Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605285 | 0.84 | HDAC6 (0.77) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| SCHEMBL20629348 | 0.82 | HDAC6 (0.67) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| SCHEMBL20605440 | 0.80 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| Tubastatin A SCHEMBL1057119 | 0.76 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| Tubastatin A SCHEMBL29356061 | 0.76 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| SCHEMBL14994555 | 0.75 | HDAC6 (0.69) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| Tubastatin A SCHEMBL18526698 | 0.75 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| Tubastatin A SCHEMBL29379429 | 0.75 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| SCHEMBL19138935 | 0.75 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 | |
| SCHEMBL19167870 | 0.75 | HDAC6 (1.00) | HDAC6HDAC2HDAC8HDAC1HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198694-B2 | HDAC6 inhibitors, with improved solubility and their uses | UNIVERSITÄT REGENSBURG (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200308174-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198694-B2 | HDAC6 inhibitors, with improved solubility and their uses | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC2 4/4885HDAC8 6/4885 |
| US-20200308174-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | HDAC6, HDAC1, HDAC2 | HDAC6 1/4885HDAC2 3/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.